Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US8663643B2 · kind B2 · utility
40Cited by
75References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2009 |
| Grant date | Mar 4, 2014 |
| Priority date | — |
| Expiry date | Dec 22, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.